RxDoctor Payments Data

Reginald Nguyen, MD

Family Medicine · Missouri City, TXNPI 1306209614

Payments from drug & device makers

$3,152in general payments, 2019–2025

Across 82 payments — averaging $38.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$671
  • Lilly USA, LLC$504
  • Pfizer$137
  • Johnson & Johnson$128
  • AbbVie$123
  • plus $467 from 11 others

What the payments were for

  • Food & beverage$3,152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,152 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$88,917
Medicare patients
197
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$161,009
MounjaroTirzepatide94$128,557
JardianceEmpagliflozin59$81,674
EliquisApixaban21$24,025
TrulicityDulaglutide11$20,778
Soliqua 100-33Insulin Glargine/Lixisenatide12$17,484
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,633
Atorvastatin Calcium314$3,293
Levothyroxine Sodium201$2,369
Rosuvastatin Calcium167$2,347
Gabapentin132$2,126
Pantoprazole Sodium127$2,041
Losartan Potassium173$2,038
Metoprolol Succinate126$1,876
Mirtazapine48$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,122$161,009136 claims
Lilly USA, LLCMounjaro, Trulicity$504$149,335105 claims
PfizerEliquis$137$24,02521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Missouri City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →